Non-Covalent Wild-Type-Sparing Inhibitors of EGFR T790M

Approximately half of EGFR mutant non-small cell lung cancer (NSCLC) patients treated with small molecule EGFR kinase inhibitors develop drug resistance associated with the EGFR T790M “gatekeeper” substitution, prompting efforts to develop covalent EGFR inhibitors, which can effectively suppress EGF...

Full description

Saved in:
Bibliographic Details
Main Authors: Lee, Ho-June, Schaefer, Gabriele, Heffron, Timothy P., Shao, Lily, Ye, Xiaofen, Sideris, Steve, Malek, Shiva, Chan, Emily, Merchant, Mark, La, Hank, Ubhayakar, Savita, Yauch, Robert L., Pirazzoli, Valentina, Politi, Katerina, Settleman, Jeff
Format: Artigo
Language:Inglês
Published: 2012
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3576842/
https://ncbi.nlm.nih.gov/pubmed/23229345
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-12-0357
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items